Introduction Globally about 1.7 million children were living with HIV in 2020. Two integrase
strand transfer inhibitors, dolutegravir and raltegravir, are increasingly used in children. We …

Despite the great strides that have been made in prevention of mother to child transmission
(PMTCT), children continue to acquire HIV. The reduction in transmission is variable, for …

Background Children with human immunodeficiency virus type 1 (HIV-1) infection have
limited options for effective antiretroviral treatment (ART). Methods We conducted an open …

Background Safe and potent antiretroviral medications in child-friendly formulations are
needed to treat young children living with HIV-1. We aimed to select dosing for a dispersible …

Background Dolutegravir-based antiretroviral therapy is a preferred first-line treatment for
adults and children living with HIV; however, very little pharmacokinetic data for dolutegravir …

Background Young children living with HIV have few treatment options. We aimed to assess
the efficacy and safety of dolutegravir-based antiretroviral therapy (ART) in children …

Background Children with HIV-associated tuberculosis (TB) have few antiretroviral therapy
(ART) options. We aimed to evaluate the safety and pharmacokinetics of dolutegravir twice …

Background Child-friendly fixed-dose combination (FDC) antiretroviral therapy (ART)
options are limited. We evaluated the pharmacokinetics, safety, and tolerability of dispersible …

Background: Clinical interpretation of the reduced dolutegravir (DTG) plasma concentrations
reported during pregnancy is complicated by its high plasma protein binding. Plasma …

Dolutegravir (DTG) is a pivotal antiretroviral medicine that has become the backbone of
several HIV programmes, especially in sub-Saharan African countries. It has recently …